TAM
ORMP icon

Telluride Asset Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Telluride Asset Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-19,371
Closed -$299K – 288
2013
Q4 		$299K Buy
+19,371
New +$149K 0.35% 69

Other funds holding ORMP

AWMDMG
Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
GIM
Greylin Investment Management Orange, Virginia $598M AUM 18.59% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Telluride Asset Management's ORMP Position: Q1 2014 in Review

Telluride Asset Management sold out of Oramed Pharmaceuticals (ORMP) in Q1 2014, closing a stake of 19,371 shares — an estimated $299K sold.

Telluride Asset Management first reported a position in ORMP in Q4 2013 and held it in 1 quarter. The position peaked at $299K in Q4 2013. 23 funds tracked by Wall St. Rank hold ORMP as of Q1 2014.

  • Telluride Asset Management reported no remaining Oramed Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • Telluride Asset Management sold 19,371 Oramed Pharmaceuticals shares in Q1 2014, an estimated $299K.
  • Telluride Asset Management first reported a position in Oramed Pharmaceuticals in Q4 2013 and held it in 1 quarter.
  • Telluride Asset Management's Oramed Pharmaceuticals position peaked at $299K in Q4 2013.
  • 23 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2014.

Based on Telluride Asset Management's 13F filing for Q1 2014, filed 14 May 2014.